Table 2 Detailed GO profiles of the DEGs in UCEC

BP

GO:0006958

Complement activation, classical pathway

38/337

137/18670

4.55E−31

4.27E−31

IGHV4-31/IGLL1/IGHV4-34/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGHV3-43/IGLV6-57/IGHV3-53/IGHV3-72/IGHV3-66/IGLV3-21/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGLV2-14/IGHV3-13/IGKV1-5/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLL5/IGLV7-43/IGHV3-30/IGHV3-64/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5

BP

GO:0002455

Humoral immune response mediated by circulating immunoglobulin

38/337

150/18670

9.97E−30

9.37E−30

IGHV4-31/IGLL1/IGHV4-34/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGHV3-43/IGLV6-57/IGHV3-53/IGHV3-72/IGHV3-66/IGLV3-21/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGLV2-14/IGHV3-13/IGKV1-5/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLL5/IGLV7-43/IGHV3-30/IGHV3-64/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5

BP

GO:0006956

Complement activation

39/337

175/18670

2.00E−28

1.88E−28

IGHV4-31/IGLL1/IGHV4-34/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGHV3-43/IGLV6-57/IGHV3-53/IGHV3-72/CFD/IGHV3-66/IGLV3-21/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGLV2-14/IGHV3-13/IGKV1-5/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLL5/IGLV7-43/IGHV3-30/IGHV3-64/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5

BP

GO:0072376

Protein activation cascade

39/337

198/18670

2.28E−26

2.14E−26

IGHV4-31/IGLL1/IGHV4-34/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGHV3-43/IGLV6-57/IGHV3-53/IGHV3-72/CFD/IGHV3-66/IGLV3-21/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGLV2-14/IGHV3-13/IGKV1-5/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLL5/IGLV7-43/IGHV3-30/IGHV3-64/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5

BP

GO:0016064

Immunoglobulin mediated immune response

39/337

218/18670

8.39E−25

7.88E−25

IGHV4-31/IGLL1/IL13RA2/IGHV4-34/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGHV3-43/IGLV6-57/IGHV3-53/IGHV3-72/IGHV3-66/IGLV3-21/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGLV2-14/IGHV3-13/IGKV1-5/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLL5/IGLV7-43/IGHV3-30/IGHV3-64/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5

BP

GO:0019724

B cell mediated immunity

39/337

221/18670

1.20E−24

1.12E−24

IGHV4-31/IGLL1/IL13RA2/IGHV4-34/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGHV3-43/IGLV6-57/IGHV3-53/IGHV3-72/IGHV3-66/IGLV3-21/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGLV2-14/IGHV3-13/IGKV1-5/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLL5/IGLV7-43/IGHV3-30/IGHV3-64/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5

BP

GO:0006959

Humoral immune response

47/337

356/18670

2.12E−24

1.99E−24

IGHV4-31/IGLL1/IGHV4-34/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGHV3-43/IGLV6-57/IGHV3-53/REG1A/IGHV3-72/CFD/IGHV3-66/IGLV3-21/IGHV4-59/IGHV3-20/IGHV3-23/KLK7/IGHV3-73/IGLV2-14/IGHV3-13/KLK3/IFNG/IGKV1-5/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/CAMP/IGLL5/IGLV7-43/IGHV3-30/KLK5/IGHV3-64/IGKV1-17/IGKV1D-12/IGKC/CXCL9/IGLC7/IGHV3-74/CXCL13/IGHG2/IGHV2-5

BP

GO:0006910

Phagocytosis, recognition

26/337

84/18670

9.61E−23

9.03E−23

IGHV4-31/IGLL1/IGHV4-34/IGHM/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5

BP

GO:0002920

Regulation of humoral immune response

29/337

134/18670

1.10E−20

1.04E−20

IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/IGLV3-21/IGHV4-59/IGHV3-23/KLK7/IGLV2-14/IGHV3-13/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/KLK5/IGKV1-17/IGKV1D-12/IGKC/IGLC7/CXCL13/IGHG2/IGHV2-5

BP

GO:0002449

Lymphocyte mediated immunity

42/337

352/18670

5.32E−20

5.00E−20

IGHV4-31/IGLL1/IL13RA2/IGHV4-34/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/ULBP2/LAG3/IGHG4/IGLV2-8/IGHV3-43/IGLV6-57/IGHV3-53/IGHV3-72/CD8A/IGHV3-66/IGLV3-21/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGLV2-14/IGHV3-13/IGKV1-5/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLL5/IGLV7-43/IGHV3-30/IGHV3-64/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5

BP

GO:0002460

Adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains

42/337

361/18670

1.29E−19

1.22E−19

IGHV4-31/IGLL1/IL13RA2/IGHV4-34/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/ULBP2/IGHG4/IGLV2-8/IGHV3-43/IGLV6-57/IGHV3-53/IGHV3-72/CD8A/IGHV3-66/IGLV3-21/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGLV2-14/IGHV3-13/IGKV1-5/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLL5/IGLV7-43/IGHV3-30/IGHV3-64/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHV3-74/CXCL13/IGHG2/IGHV2-5

BP

GO:0030449

Regulation of complement activation

26/337

115/18670

4.87E−19

4.57E−19

IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHG2/IGHV2-5

BP

GO:2000257

Regulation of protein activation cascade

26/337

116/18670

5.70E−19

5.35E−19

IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHG2/IGHV2-5

BP

GO:0050853

B cell receptor signaling pathway

27/337

129/18670

6.11E−19

5.74E−19

IGHV4-31/IGLL1/IGHV4-34/IGHM/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGLC7/CD22/IGHV3-74/IGHG2/IGHV2-5

BP

GO:0006911

Phagocytosis, engulfment

26/337

118/18670

7.88E−19

7.41E−19

IGHV4-31/IGLL1/IGHV4-34/IGHM/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5

BP

GO:0006909

Phagocytosis

41/337

369/18670

1.63E−18

1.53E−18

IGHV4-31/IGLL1/IGHV4-34/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/SIRPG/IGHG4/IGLV2-8/IGHV3-43/APOA1/IGLV6-57/IGHV3-53/IGHV3-72/IGHV3-66/IGLV3-21/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGLV2-14/IGHV3-13/IFNG/IGKV1-5/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLL5/IGLV7-43/IGHV3-30/IGHV3-64/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5

BP

GO:0099024

Plasma membrane invagination

26/337

127/18670

5.10E−18

4.79E−18

IGHV4-31/IGLL1/IGHV4-34/IGHM/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5

BP

GO:0002377

Immunoglobulin production

30/337

193/18670

2.21E−17

2.08E−17

IGLV5-45/IL13RA2/IGLV8-61/IGKV3D-15/IGLV1-44/IGKV2-30/IGKV5-2/IGLV2-8/IGLV6-57/IGKV1-27/IGLV3-21/IGLV1-36/IGLV2-14/IGLV4-69/IGLV3-16/IGKV1-5/IGKV1D-43/TRDV1/IGLV3-19/IGLV7-43/IGKV1D-13/IGKV1-17/IGKV1D-12/TRAV19/IGKV6D-21/IGKC/TRAV14DV4/CD22/IGLV7-46/IGLV4-60

BP

GO:0010324

Membrane invagination

26/337

135/18670

2.34E−17

2.20E−17

IGHV4-31/IGLL1/IGHV4-34/IGHM/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5

BP

GO:0002433

Immune response-regulating cell surface receptor signaling pathway involved in phagocytosis

26/337

139/18670

4.58E−17

4.31E−17

IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHG2/IGHV2-5

BP

GO:0038096

Fc-gamma receptor signaling pathway involved in phagocytosis

26/337

139/18670

4.58E−17

4.31E−17

IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHG2/IGHV2-5

BP

GO:0038094

Fc-gamma receptor signaling pathway

26/337

142/18670

7.34E−17

6.90E−17

IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHG2/IGHV2-5

BP

GO:0050871

Positive regulation of B cell activation

26/337

142/18670

7.34E−17

6.90E−17

IGHV4-31/IGLL1/IGHV4-34/IGHM/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5

BP

GO:0002431

Fc receptor mediated stimulatory signaling pathway

26/337

145/18670

1.22E−16

1.14E−16

IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHG2/IGHV2-5

BP

GO:0070613

Regulation of protein processing

28/337

180/18670

2.69E−16

2.52E−16

IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/SPON1/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/CCBE1/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHG2/IGHV2-5

BP

GO:0002440

Production of molecular mediator of immune response

34/337

286/18670

3.04E−16

2.86E−16

IGLV5-45/IL13RA2/IGLV8-61/IGKV3D-15/IGLV1-44/IGKV2-30/IGKV5-2/IGLV2-8/APOA1/IGLV6-57/IGKV1-27/IGLV3-21/IGLV1-36/KLK7/IGLV2-14/IGLV4-69/KLK3/IGLV3-16/IGKV1-5/IGKV1D-43/TRDV1/IGLV3-19/IGLV7-43/IGKV1D-13/KLK5/IGKV1-17/IGKV1D-12/TRAV19/IGKV6D-21/IGKC/TRAV14DV4/CD22/IGLV7-46/IGLV4-60

BP

GO:1903317

Regulation of protein maturation

28/337

182/18670

3.37E−16

3.16E−16

IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/SPON1/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/CCBE1/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHG2/IGHV2-5

BP

GO:0002673

Regulation of acute inflammatory response

26/337

159/18670

1.14E−15

1.07E−15

IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHG2/IGHV2-5

BP

GO:0002429

Immune response-activating cell surface receptor signaling pathway

42/337

473/18670

1.29E−15

1.22E−15

IGHV4-31/IGLL1/IGHV4-34/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGHV3-43/IGLV6-57/IGHV3-53/IGHV3-72/IGHV3-66/IGLV3-21/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGLV2-14/IGHV3-13/IGKV1-5/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLL5/MUCL1/TRBV7-9/IGLV7-43/IGHV3-30/IGHV3-64/IGKV1-17/IGKV1D-12/TRAV19/IGKC/IGLC7/CD22/IGHV3-74/IGHG2/IGHV2-5

BP

GO:0016485

Protein processing

35/337

328/18670

2.60E−15

2.44E−15

IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/SPON1/KLK6/IGLV3-21/IGHV4-59/IGHV3-23/PCSK1N/IGLV2-14/IGHV3-13/KLK3/CCBE1/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/KLK1/IGHV3-30/PCSK9/SCG5/IGKV1-17/IGKV1D-12/IGKC/IGLC7/CPXM2/IGHG2/IGHV2-5

BP

GO:0050864

Regulation of B cell activation

27/337

184/18670

4.15E−15

3.90E−15

IGHV4-31/IGLL1/IGHV4-34/IGHM/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGLC7/CD22/IGHV3-74/IGHG2/IGHV2-5

BP

GO:0008037

Cell recognition

27/337

215/18670

2.20E−13

2.07E−13

IGHV4-31/IGLL1/IGHV4-34/IGHM/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/CRTAC1/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5

BP

GO:0002526

Acute inflammatory response

27/337

220/18670

3.81E−13

3.58E−13

IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/IL1A/IGLC7/IGHG2/IGHV2-5

BP

GO:0051604

Protein maturation

35/337

397/18670

8.46E−13

7.95E−13

IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/SPON1/KLK6/IGLV3-21/IGHV4-59/IGHV3-23/PCSK1N/IGLV2-14/IGHV3-13/KLK3/CCBE1/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/KLK1/IGHV3-30/PCSK9/SCG5/IGKV1-17/IGKV1D-12/IGKC/IGLC7/CPXM2/IGHG2/IGHV2-5

BP

GO:0038095

Fc-epsilon receptor signaling pathway

23/337

169/18670

4.43E−12

4.16E−12

IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGLV2-8/IGLV6-57/IGHV3-53/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/IGKV1-5/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHV2-5

BP

GO:0042742

Defense response to bacterium

31/337

330/18670

5.32E−12

5.00E−12

IGHV4-31/IGLL1/IGHV4-34/IGHM/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/KLK7/IGHV3-73/IGHV3-13/KLK3/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/CAMP/IGLL5/IGHV3-30/KLK5/IGHV3-64/IGKC/IGLC7/IGHV3-74/CXCL13/IGHG2/IGHV2-5

BP

GO:0051251

Positive regulation of lymphocyte activation

31/337

334/18670

7.18E−12

6.74E−12

IGHV4-31/IGLL1/IGHV4-34/IGHM/SIRPG/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/CCL5/TNFSF9/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IFNG/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGF2/IGLC7/IGHV3-74/IGHG2/IGHV2-5

BP

GO:0038093

Fc receptor signaling pathway

26/337

241/18670

2.36E−11

2.22E−11

IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHG2/IGHV2-5

BP

GO:0051249

Regulation of lymphocyte activation

36/337

485/18670

5.50E−11

5.17E−11

IGHV4-31/IGLL1/IGHV4-34/IGHM/SOX11/SIRPG/LAG3/IGHG4/FOXN1/IGHV3-43/IGHV3-53/TIGIT/IGHV3-72/CCL5/TNFSF9/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IFNG/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGF2/IGLC7/CD22/IGHV3-74/IGHG2/IGHV2-5

BP

GO:0050851

Antigen receptor-mediated signaling pathway

29/337

316/18670

5.80E−11

5.45E−11

IGHV4-31/IGLL1/IGHV4-34/IGHM/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/TRBV7-9/IGHV3-30/IGHV3-64/TRAV19/IGKC/IGLC7/CD22/IGHV3-74/IGHG2/IGHV2-5

BP

GO:0002696

Positive regulation of leukocyte activation

31/337

380/18670

2.01E−10

1.89E−10

IGHV4-31/IGLL1/IGHV4-34/IGHM/SIRPG/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/CCL5/TNFSF9/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IFNG/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGF2/IGLC7/IGHV3-74/IGHG2/IGHV2-5

BP

GO:0002697

Regulation of immune effector process

34/337

458/18670

2.32E−10

2.18E−10

IL13RA2/IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/ULBP2/LAG3/IGHG4/IGLV2-8/APOA1/IGLV6-57/IGHV3-53/IGLV3-21/IGHV4-59/IGHV3-23/KLK7/IGLV2-14/IGHV3-13/IFNG/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/KLK5/IGKV1-17/IGKV1D-12/IGKC/IGLC7/CD22/IGHG2/IGHV2-5

BP

GO:0050867

Positive regulation of cell activation

31/337

394/18670

4.90E−10

4.60E−10

IGHV4-31/IGLL1/IGHV4-34/IGHM/SIRPG/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/CCL5/TNFSF9/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IFNG/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGF2/IGLC7/IGHV3-74/IGHG2/IGHV2-5

BP

GO:0042113

B cell activation

27/337

310/18670

1.14E−09

1.07E−09

IGHV4-31/IGLL1/IGHV4-34/IGHM/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGLC7/CD22/IGHV3-74/IGHG2/IGHV2-5

BP

GO:0006898

Receptor-mediated endocytosis

27/337

316/18670

1.74E−09

1.63E−09

APOB/IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGLV2-8/APOA1/IGLV6-57/IGHV3-53/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/IGKV1-5/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/PCSK9/IGKV1-17/IGKV1D-12/IGKC/AMBP/IGLC7/IGHV2-5

BP

GO:0050900

Leukocyte migration

34/337

499/18670

2.23E−09

2.10E−09

IGLL1/APOB/IGHV4-34/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/SIRPG/IGLV2-8/IGLV6-57/IGHV3-53/CCL5/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/IGKV1-5/IGHV2-70/IGHV1-69/IGLV3-19/MAG/SLC7A10/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/CXCL9/IGLC7/ATP1B2/EDN3/CXCL13/IGHV2-5

BP

GO:0050727

Regulation of inflammatory response

30/337

485/18670

3.25E−07

3.05E−07

IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/APOA1/IGLV6-57/IGHV3-53/CCL5/GBP5/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/LRFN5/IGLC7/IGHG2/IGHV2-5

BP

GO:0042475

Odontogenesis of dentin-containing tooth

10/337

90/18670

0.000340129

0.000319658

WNT6/KLK4/SCN5A/FGF4/DLX3/BMP2/KLK5/CA2/FGF8/WNT10A

BP

GO:0031128

Developmental induction

6/337

34/18670

0.001891025

0.001777212

SIX3/WNT4/HOXC11/BMP2/FGF8/GDNF

BP

GO:0009952

Anterior/posterior pattern specification

14/337

219/18670

0.002987205

0.002807418

SIX3/HOXC8/HOXC6/ALX1/CRB2/FOXC2/HOXC10/HOXC11/BMP2/FGF8/HOXC9/CDX1/BARX1/NKD1

BP

GO:0021984

Adenohypophysis development

4/337

13/18670

0.004101352

0.003854509

WNT4/BMP2/FGF8/SOX2

BP

GO:0003002

Regionalization

18/337

351/18670

0.004611317

0.004333781

SIX3/HOXC8/HOXC6/ALX1/NKX2-2/CRB2/FOXC2/HOXC10/HOXC11/BMP2/FGF8/WNT7A/GDNF/HOXC9/CDX1/BARX1/DMRTA2/NKD1

BP

GO:0045165

Cell fate commitment

15/337

270/18670

0.007471561

0.00702188

WNT6/WNT4/FOXN1/NKX2-2/WNT16/FOXC2/HOXC10/BMP2/FGF8/TENM4/WNT7A/WNT5B/SOX2/WNT10A/DMRTA2

BP

GO:0098742

Cell–cell adhesion via plasma-membrane adhesion molecules

15/337

273/18670

0.008281927

0.007783474

PTPRT/APOA1/CLDN9/CRB2/CDH22/BMP2/MAG/LRRC4C/CLDN19/PCDH10/TENM4/CLDN6/TRO/PCDHB5/LRFN5

BP

GO:0042476

Odontogenesis

10/337

132/18670

0.008307838

0.007807825

WNT6/KLK4/SCN5A/FGF4/DLX3/BMP2/KLK5/CA2/FGF8/WNT10A

BP

GO:0061844

Antimicrobial humoral immune response mediated by antimicrobial peptide

7/337

73/18670

0.01961805

0.018437324

REG1A/KLK7/KLK3/CAMP/KLK5/CXCL9/CXCL13

BP

GO:0007389

Pattern specification process

19/337

446/18670

0.028662281

0.026937221

SIX3/HOXC8/WNT6/HOXC6/ALX1/NKX2-2/CRB2/FOXC2/HOXC10/HOXC11/BMP2/FGF8/WNT7A/GDNF/HOXC9/CDX1/BARX1/DMRTA2/NKD1

BP

GO:0001759

Organ induction

4/337

22/18670

0.032449794

0.03049678

HOXC11/BMP2/FGF8/GDNF

BP

GO:0048762

Mesenchymal cell differentiation

12/337

219/18670

0.035439505

0.033306553

ALX1/SOX11/WNT4/FGF19/CRB2/WNT16/FOXC2/BMP2/FGF8/GDNF/EDN3/WNT10A

BP

GO:0001658

Branching involved in ureteric bud morphogenesis

6/337

59/18670

0.035439505

0.033306553

WNT6/ADAMTS16/WNT4/BMP2/FGF8/GDNF

BP

GO:0016338

Calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules

4/337

23/18670

0.036228036

0.034047626

CLDN9/BMP2/CLDN19/CLDN6

BP

GO:0045109

Intermediate filament organization

4/337

23/18670

0.036228036

0.034047626

TCHH/NEFH/GFAP/KRT71

BP

GO:0021871

Forebrain regionalization

4/337

24/18670

0.042179675

0.039641061

SIX3/BMP2/FGF8/DMRTA2

BP

GO:0046886

Positive regulation of hormone biosynthetic process

3/337

11/18670

0.042595197

0.040031574

WNT4/IFNG/PPARGC1A

BP

GO:0048864

Stem cell development

7/337

85/18670

0.042595197

0.040031574

ALX1/SOX11/FGF19/FOXC2/WNT7A/GDNF/EDN3

BP

GO:0021983

Pituitary gland development

5/337

42/18670

0.044221556

0.04156005

SIX3/WNT4/BMP2/FGF8/SOX2

BP

GO:0070268

Cornification

8/337

112/18670

0.04586542

0.043104977

TCHH/FLG/KRT71/KRT36/KRT5/KLK5/KRT31/KRT34

BP

GO:0008211

Glucocorticoid metabolic process

4/337

25/18670

0.04586542

0.043104977

WNT4/APOA1/BMP2/SERPINA6

CC

GO:0019814

Immunoglobulin complex

51/354

159/19717

1.95E−47

1.78E−47

IGHV4-31/IGLV5-45/IGLL1/IGLV8-61/IGHV4-34/IGKV3D-15/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGHV3-43/IGLV6-57/IGHV3-53/IGHV3-72/IGHJ1/IGKV1-27/IGHV3-66/IGLV3-21/IGHV4-59/IGHV3-20/IGLV1-36/IGHV3-23/IGHV3-73/IGLV2-14/IGLV4-69/IGHV3-13/IGLV3-16/IGKV1-5/IGKV1D-43/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLL5/IGLV7-43/IGKV1D-13/IGHV3-30/IGHV3-64/IGKV1-17/IGKV1D-12/IGKV6D-21/IGKC/IGLC7/IGHV3-74/IGLV7-46/IGLV4-60/IGHG2/IGHV2-5

CC

GO:0042571

Immunoglobulin complex, circulating

26/354

72/19717

3.37E−-25

3.07E−25

IGHV4-31/IGLL1/IGHV4-34/IGHM/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5

CC

GO:0009897

External side of plasma membrane

39/354

393/19717

3.99E−16

3.63E−16

IGHV4-31/IGLL1/IL13RA2/IGHV4-34/IGHM/CNTFR/ULBP2/CCR10/LAG3/LY6G6C/IGHG4/IGHV3-43/GPIHBP1/IGHV3-53/IGHV3-72/CD8A/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/GFRA2/IGHV3-13/GFRA1/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/PCSK9/IGHV3-64/FGF8/IGKC/CXCL9/IGLC7/IGHV3-74/IGHG2/IGHV2-5

CC

GO:0072562

Blood microparticle

15/354

147/19717

5.34E−06

4.86E−06

IGHM/IGKV2-30/IGHG4/APOA1/IGLV3-21/IGHV3-23/IGHV3-13/IGKV1-5/IGHG3/IGKV1-17/IGKV1D-12/IGKC/AMBP/PON1/IGHG2

CC

GO:0042101

T cell receptor complex

11/354

127/19717

0.001186365

0.001080471

TRBV7-6/CD8A/TRBV4-2/TRAV21/TRDV1/TRBV7-9/TRAV19/TRAV12-1/TRAV14DV4/TRBV4-1/TRAV26-2

CC

GO:0098802

Plasma membrane receptor complex

15/354

295/19717

0.016378041

0.01491615

GRIK5/CNTFR/TRBV7-6/CD8A/TRBV4-2/TRAV21/TRDV1/BMP2/TRBV7-9/CHRNA3/TRAV19/TRAV12-1/TRAV14DV4/TRBV4-1/TRAV26-2

MF

GO:0003823

Antigen binding

41/300

160/17697

3.33E−34

2.97E−34

IGHV4-31/IGLL1/IGHV4-34/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/LAG3/IGHG4/IGLV2-8/IGHV3-43/IGLV6-57/IGHV3-53/IGHV3-72/IGHV3-66/IGLV3-21/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGLV2-14/IGHV3-13/IGKV1-5/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLL5/TRBV7-9/IGLV7-43/IGHV3-30/IGHV3-64/IGKV1-17/IGKV1D-12/TRAV19/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5

MF

GO:0034987

Immunoglobulin receptor binding

26/300

76/17697

5.43E−25

4.85E−25

IGHV4-31/IGLL1/IGHV4-34/IGHM/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5

MF

GO:0005109

Frizzled binding

8/300

39/17697

3.98E−05

3.55E−05

WNT6/MYOC/WNT4/RSPO4/WNT16/WNT7A/WNT5B/WNT10A

MF

GO:0048018

Receptor ligand activity

23/300

482/17697

0.001065684

0.000951118

WNT4/FGF19/APOA1/REG1A/CCL5/TNFSF9/FGF4/INSL4/SLURP1/IFNG/TRH/FGF20/BMP2/FGF8/CXCL9/WNT7A/GDNF/IL1A/FGF3/IGF2/EDN3/WNT10A/CXCL13

MF

GO:0005104

Fibroblast growth factor receptor binding

5/300

25/17697

0.00536912

0.004791912

FGF19/FGF4/FGF20/FGF8/FGF3

MF

GO:0004252

Serine-type endopeptidase activity

10/300

160/17697

0.033673709

0.030053615

KLK4/KLK6/CFD/KLK7/KLK3/GZMH/KLK8/KLK1/KLK5/PCSK9

MF

GO:0046873

Metal ion transmembrane transporter activity

18/300

438/17697

0.036391745

0.032479448

GRIK5/TTYH1/GPM6A/CACNA1S/SCN5A/KCNE5/LRRC55/KCNJ15/SLC5A8/JPH3/CACNG6/CACNA1I/ATP2A3/SLC6A15/SLC13A5/SCN1A/SLC13A2/ATP1B2

MF

GO:0022839

Ion gated channel activity

15/300

334/17697

0.037581202

0.033541033

GRIK5/TTYH1/CACNA1S/SCN5A/ANO2/KCNE5/LRRC55/KCNJ15/P2RX2/GABRA3/JPH3/CACNG6/CACNA1I/CHRNA3/SCN1A

MF

GO:0022836

Gated channel activity

15/300

343/17697

0.043831647

0.039119522

GRIK5/TTYH1/CACNA1S/SCN5A/ANO2/KCNE5/LRRC55/KCNJ15/P2RX2/GABRA3/JPH3/CACNG6/CACNA1I/CHRNA3/SCN1A

MF

GO:0070325

Lipoprotein particle receptor binding

4/300

26/17697

0.044441069

0.039663429

APOB/APOA1/PCSK9/SYT1

MF

GO:0008236

Serine-type peptidase activity

10/300

182/17697

0.049388397

0.044078894

KLK4/KLK6/CFD/KLK7/KLK3/GZMH/KLK8/KLK1/KLK5/PCSK9

MF

GO:0005343

Organic acid:sodium symporter activity

4/300

28/17697

0.049388397

0.044078894

SLC5A8/SLC6A15/SLC13A5/SLC13A2

MF

GO:0017171

Serine hydrolase activity

10/300

186/17697

0.049706953

0.044363203

KLK4/KLK6/CFD/KLK7/KLK3/GZMH/KLK8/KLK1/KLK5/PCSK9